UK’s Johnson may ease some COVID-19 measures before mid-Feb, Sky reports
British Prime Minister Boris Johnson is looking at the potential to relax some COVID-19 measures before mid-February, a Sky News reporter said on Monday.
Related Articles
Sanofi profit slips on generic competition and currency effects
Sanofi’s first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent,…
West Pharma posts beat-and-raise quarter aided by strong demand for injectables
West Pharmaceutical Services on Thursday beat quarterly profit estimates and raised its annual profit forecast, banking on rising demand for cartridges and syringes used to…
Labcorp beats quarterly estimates on strong testing demand
Labcorp beat Wall Street expectations for first-quarter profit on Thursday, as growing demand for specialty tests boosted sales at its diagnostics business.
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.
Bristol Myers posts quarterly loss, revenue rises 5%
Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a…
India’s Glenmark Life Sciences posts lower Q4 profit as Red Sea crisis hurts API business
Indian drugmaker Glenmark Life Sciences posted its first drop in profit for six quarters on Thursday as its mainstay active pharmaceutical ingredients (API) business was…
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and…
AstraZeneca leaps after smashing first-quarter forecasts
AstraZeneca sailed past market expectations for quarterly revenue and profit on Thursday, boosted by demand for its blockbuster drugs and steady sales from partnered medicines…
UK-listed drugmaker Indivior seeks shareholder nod for US listing
UK-listed drugmaker Indivior plans to seek shareholder approval next month for a primary listing in the United States, the company said on Thursday, which would…
Sanofi profit slips on generic competition and currency effects
Sanofi’s first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent,…